Apr. 14, 2026
[IMPORTANT] Notice Regarding Unauthorized Cross-border Distribution of Our Prescription Drugs Intended for the Japanese Market
In recent years, Teijin Pharma has become aware that our prescription drugs packaged for the Japanese market are leaked and sold to countries other than Japan through unauthorized cross-border transactions, such as foreign e-commerce sites and other online platforms. However, products leaked and sold through these unauthorized channels, which are completely separate from our authorized distribution network for the Japanese market, cannot be guaranteed by Teijin Pharma with respect to their quality, safety, or efficacy. Furthermore, we cannot guarantee that these products are genuine products manufactured and marketed to Japan by Teijin Pharma.
Teijin Pharma assumes no responsibility whatsoever for any issues, health hazards, losses, or damages caused by products obtained through these unauthorized channels. We strongly urge you to exercise extreme caution when purchasing or using such products.
-The prescription drugs manufactured and marketed by Teijin Pharma in Japan are subject to the Pharmaceuticals and Medical Devices Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices) and other related pharmaceutical laws and regulations in Japan.
-In accordance with these regulations, we supply our pharmaceutical products to medical institutions and pharmacies only in Japan through duly licensed pharmaceutical wholesalers and other authorized distribution channels. This ensures the quality, safety, and efficacy of our products.
For inquiries regarding this matter, please contact us through the following website:
＜Inquiries in Japanese＞ ＜Inquiries in English＞